Chemicals

Hexyl nicotinoate

We are Hexyl nicotinoate CAS:23597-82-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 23597-82-2

Product Name: Hexyl nicotinoate

Other Name:

Hexyl nicotinoate

Hexyl pyridine-3-carboxylate

N-hexyl nicotinoate

Nicotinsaeure-hexylester

Nicotinic Acid Hexyl Ester

3-Hexyloxycarbonylpyridine

Density: 1,02 g/cm3

Boiling Point: 140°C

Molecular Formula: C12H17NO2

Molecular Weight: 207.26900

Flash Point: 140ºC

Exact Mass: 207.12600

PSA: 39.19000

LogP: 2.81870

Vapour Pressure: 0.000181mmHg at 25°C

Index of Refraction: 1.495

Specification

Appearance: White Powder

Assay: ≥98.0%

Loss on drying: ≤1%

Application

Hexyl nicotinate can be used as an intermediate in pharmaceutical synthesis.

This product has the effect of decomposing fat and reducing local fat. The main component of fat is fatty acid triglycerides. This product can be broken down into glycerin and fatty acids through skin penetration, which makes the skin slightly warm and red, thereby reducing cellulite. Of water and facilitates the removal of fatty acids from these tissues.

Package: 25kg/drum, can also be designed according to customer requirements.

Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Hexyl nicotinoate

Related News: The Company selected the top-performing clone for generation of the master engineered iPSC bank for GMP production of FT819.2-Bromo-3-Chloro-5-(Trifluoromethyl)Pyridine The Company selected the top-performing clone for generation of the master engineered iPSC bank for GMP production of FT819.173194-95-1 Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.757251-39-1 Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule.

Product Name
2,2-Bis[3,5-dibromo-4-(2,3-dibromo-2-methylpropoxy)phenyl]propane	View Details
2-bromo-1-(4-iodophenyl)ethanone	View Details
3-(2-chloropyrimidin-4-yl)-1-methylindole	View Details